Cytokinetics (CYTK) Tops Q3 EPS by 8c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
CIX, ARIS, COHR, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.37), $0.08 better than the analyst estimate of ($1.45). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $40.61 million.
Guidance
The company is reaffirming its full year 2026 financial guidance:
GAAP combined R&D and SG&A Expense: $860 million to $890 million
Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expense: $140 million to $130 million
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
- ArcelorMittal (MT) Tops Q3 EPS by 36c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
